Allegra 180 mg, 60 mg, and Allegra D-12 are indicated for the relief of symptoms associated with seasonal allergies. Sanofi-aventis has applied to the FDA for the Rx-to-OTC switch of these drugs. Prior to generic competition entering the Fexofenadine Rx market in 2005, Allegra 180 mg and 60 mg had combined annual sales of approximately US$1.5 billion, and in 2009, Allegra D-12 had annual sales of US$600 million.

Perrigo’s Chairman and CEO, Mr Joseph C Papa, stated, “This is another example of Perrigo’s strategic focus on making quality healthcare more affordable to American consumers by introducing new Rx-to-OTC switch products”.

US-based Perrigo develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, infant formula, active pharmaceutical ingredients and consumer products. The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market.

Reference:

Perrigo Company Press Release, Perrigo acquires exclusive sales and distribution rights to OTC store brand versions of Allegra and Allegra D-12 from Teva. 29 June 2010